Pharmaceutical Industry News Archive
Get news by email or subscribe to our news feeds.
News Archive for April 2011
April 1, 2011
- Neuro-Biotech Corp. & Auric Pharma Science Announce Completion of Buy Out Offer
- Amgen Wary Of Any Change To R.I. Corporate Tax
- Pharmaceutical Companies Worried About Chicken Plant
- ACRO Files Brief with U.S. Supreme Court to Support Availability of Prescription Data for Use in Clinical and Medical Research
- Invida Forms Unique Partnership with Roche in Korea
- Recommendations on Labelling And Packaging For Non-Prescription Medicines Released For Consultation
- Kitasato Daiichi Sankyo Vaccine Joint Venture Company to Begin Operations
- Eisai Appoints First Locally-Hired President At Its Chinese Subsidiary Eisai China Inc.
- Takeda Appoints New Leadership for its European Pharmaceutical Development Organization
- ACADIA Pharmaceuticals Announces Extension of Drug Discovery Collaboration with Allergan, Inc.
- Jury Verdict Mixed In Contamination Case
- Patient Groups, Former HHS Secretaries, U.S. Chamber of Commerce, and More Than 50 Key Healthcare Stakeholders and Researchers Urge Supreme Court to Reject Three State Laws Outlawing Commercial Use of Prescription Data
April 4, 2011
- Pfizer to Sell Capsugel to KKR
- Dr. Reddy's Officially Takes Over GSK Plant In Bristol, England
- Experts: NJ Drug Industry Should Partner Abroad
- March Of Dimes Abandons KV Pharmaceutical
- Santa Clara County Loses Drug Suit At High Court
- Philosophical Fight Continues Over Drug Database in Florida
- Forest Laboratories Announces Amendment to Merger Agreement and Extends Tender Offer to Acquire Clinical Data, Inc.
- Shionogi Announces New US Leadership
- Pfizer Receives 'Refuse To File' Letter From FDA
- IBM and The Institute of Bioengineering and Nanotechnology Find Breakthrough for MRSA Treatment
- Daiichi Sankyo Completes Plexxikon Acquisition
- Bayer HealthCare Selects the State of New Jersey for East Coast Site Consolidation
- John P. Gargiulo Named President and CEO of Daiichi Sankyo, Inc.
- Millennium Laboratories and the Millennium Research Institute Support Tufts Health Care Institute Program on Opioid Risk Management
- Cubist Pharmaceuticals Settles CUBICIN Patent Litigation with Teva
April 5, 2011
- FDA Launches Consumer-friendly Web Search for Consumers During Recalls
- Incyte Achieves $15 Million Milestone for c-MET Inhibitor Oncology Program
- FDA Approves Extended-Release Version of HIV Drug
- Cubist, Teva Settle Cubicin Patent Dispute
- Unilife Realigns Operations to Drive Sales and Support Commercial Production of Unifill Syringes
- Boehringer Ingelheim Maintains Sales Level/Course Set For The Future: Product Pipeline Well-Filled
- Merck to Acquire Inspire Pharmaceuticals, Inc.
- Pneumonia Death Rate Lower Among People Who Take Statins
- BTG plc: Close period update
- Retention and Expansion of Bayer HealthCare's East Coast Operations Reaffirms Positive Impact of Christie Administration's Policies
- Bayer to Consolidate NJ Operations, Add Jobs
- Express Scripts Injects $226 Million Into Arizona Economy, Study Finds
- Sanofi-aventis Successfully Completes Exchange Offer for Genzyme Corporation
April 6, 2011
- Drug Makers Pay Some Idaho Doctors to Speak
- Idaho Collects Millions from Drug Companies
- Cephalon Formerly Rejects Takeover Bid by Canadian Pharmaceutical Giant Valeant
- Physician Mobile Use Grows 45%; Apple Dominates Android and Blackberry
- Cephalon's Board of Directors Rejects Valeant Pharmaceuticals' Unsolicited Proposal
- Shire Files Lawsuit Against Watson Pharmaceuticals, Inc. for Infringement of ADDERALL XR(R) Patents and for Breach of Contract
- Optimer Pharmaceuticals and Cubist Pharmaceuticals Announce Collaboration to Co-Promote Dificid (Fidaxomicin) for Clostridium difficile Infection in the United States
- More Than 75,000 Physicians Are Participating in Online Sampling Programs on Monthly Basis
- Plaintiffs Appeal Against Court Ruling Over Iressa Drug Side Effects
- Fabry Disease Group Moves to Pry Patent From Genzyme
- Roche Diabetes Care in the U.S. Turns to Social Media to Promote Diabetes Education, Awareness and Advocacy
- FDA Acts to Prevent Contamination Problems With Triad Antiseptic Products
April 7, 2011
- FDA MedWatch - Yervoy (ipilimumab): Risk Evaluation and Mitigation Strategy (REMS) - Severe Immune-Mediated Adverse Reactions
- SuperGen and Astex Therapeutics Enter Definitive Merger Agreement
- Meda to License Elidel to Valeant Pharmaceuticals
- Novartis Sells Global Rights to Elidel, A Medicine to Treat Atopic Dermatitis
- Shire files Lawsuit Against Watson Pharmaceuticals, Inc. for Infringement of ADDERALL XR pPatents and for Breach of Contract
- Eisai Expands into Brazil
April 8, 2011
- Alcon Shareholders Approve Merger with Novartis
- GSK Reveals Job Plan to Swap India for Scotland ; Glaxo Chief Explains Move to Scotland
- Watson Confirms Vigamox Patent Challenge
- Cephalon Recommends Shareholders Reject Valeant Nominees
- Cangene Reorganizes Workforce in Its Canadian Operations to Increase Efficiency
- McDonald Hopkins Law Firm Alert: Recent Court of Appeals Decision Highlights the Need to Properly Define the Role of Sales Representatives
- Amgen Establishes Commercial Operations in Brazil
- StemCells, Inc. Discontinues Batten Disease Program
- Watson Pharma Applies to Make Generic Vigamox
- Analysts: Moving Pfizer Antibacterials Unit May Delay Critical Research
- Pfizer Enters Partnership to Focus on Rare Diseases
- Novartis Shareholders Approve Merger of Alcon into Novartis
April 11, 2011
- FDA Drug Safety Communication: Ongoing Safety Review of Revlimid (lenalidomide) and Possible Increased Risk of Developing New Malignancies
- Johnson & Johnson to Pay $21.4 Million to Resolve FCPA, Oil for Food Violations
- Actress Sues After Face Used in Prozac Ad
- Pfizer and Medivation Announce Results From Phase 3 Horizon Trial of Dimebon in Huntington Disease
- Heptares and Takeda Initiate Drug Discovery Collaboration Focused on GPCR Linked to CNS Disorders
- immatics to Receive Support From Pfizer for its Pivotal Phase III Study (IMPRINT) With IMA901, a Therapeutic Vaccine for Advanced Renal Cell Cancer Patients
- J&J Pays $70M to Settle Corruption Charges
- FDA Cancels Mannkind Meeting on Shutdown Danger
- Merck & Co., Inc., and Sun Pharma Establish Joint Venture to Develop and Commercialize Novel Formulations and Combinations of Medicines in Emerging Markets
April 12, 2011
- Durect Pain Patch Fails in Midstage Study
- New Target for Developing Effective Anti-Depressants
- BG-12 Positive in First Phase III; Biogen Poised for Oral MS Entry
April 13, 2011
- Lorus Therapeutics Reports has Q3 Net Loss of $1.6 Million
- Forest Laboratories Announces Successful Completion of Tender Offer for Securities of Clinical Data, Inc.
April 14, 2011
- Survey Reveals PatientsLikeMe Helps People With Epilepsy Improve Seizure Understanding and Medication Adherence
- Indigenus Global Network Unites Under a Single LLC
- SEC Charges Former Hedge Fund Portfolio Manager With Insider Trading
- Watson Pharmaceuticals Terminates Drug Development Agreement with Stellar
- Roche Sales Down 9 Percent in First Quarter on Currencies, Weaker Tamiflu Orders
- FDA Seeks More Power to Police Drug Import Safety
- Forest Labs CEO to Challenge HHS Move
- Ortho-McNeil Neurologics Voluntarily Recalls Two Lots of Topamax
- FDA MedWatch - Tumor Necrosis Factor (TNF) blockers, Azathioprine and/or Mercaptopurine: Update on Reports of Hepatosplenic T-Cell Lymphoma in Adolescents and Young Adults
- Autism and Vaccines Researcher for CDC, Indicted for Fraud and Money-Laundering
April 15, 2011
- Weight-Loss Drugs Alli and Xenical Should Be Removed from the Market, Public Citizen Tells FDA
- Galapagos NV (BE) - Galapagos Discontinues Phase II Trial for GLPG0259, Focuses Resources on Other Rheumatoid Arthritis Programs
- Former Pharmaceutical Company Lawyer Charged with Obstruction and Making False Statements
- Merck and Johnson & Johnson Reach Agreement on Distribution Rights for REMICADE and SIMPONI
- Octapharma: European Medicines Agency (EMA) Recommends to Lift the Suspension of the Marketing Authorization of octagam® (human normal immunoglobulin for i.v. administration, 50 mg/ml, 5%) and octagam®10% (normal IgG for i.v.)
- European Medicines Agency Concludes Class Review of bisphosphonates and Atypical Fractures
- GlaxoSmithKline Announces Plan to Sell Aiken Location
- Merck Commences Tender Offer for all Outstanding Shares of Inspire Pharmaceuticals, Inc.
- Former Merck CEO Clark Received 65 Percent Increase in Total Compensation Last Year
April 18, 2011
- FDA Warns Patients Over Teva's Reflux Drug
- Sanofi-Aventis Invests $2.1 Million in Hadasit Bio Portfolio co Kahr
- Johnson & Johnson, Synthes Reported in Merger Talks
- Lilly Reports First-Quarter 2011 Results
- Unfavorable Feelings About Television Advertising for Prescription Drugs From Physicians and Public, According to AdSAM SenseUS
- Baxter Announces the Acquisition of Prism Pharmaceuticals
- ImpactRx Acquired by Symphony Technology Group
- Susquehanna Growth Equity Acquires MediMedia Information Technologies, LLC
- CROM Acquires MSOURCE, a Mid-size European Clinical Research Organisation (CRO) Specializing in Staffing Solutions and Medical Device Trials, Creating CROMSOURCE
April 19, 2011
- Johnson & Johnson Reports 2011 First-Quarter Results
- New Generation of Blood Thinners Offers Patients Easier-to-Use Options
- Forest Laboratories, Inc. Reports Fiscal Year Fourth Quarter 2011 Earnings Per Share of $1.12
- Novartis Makes Strong Start for the Year
- Viropharma Loses Challenge to Generic Drug Rule
- On the Call: Eli Lilly CFO Rice on Restructuring
- IMS Institute Reports U.S. Spending on Medicines Grew 2.3 Percent in 2010, to $307.4 Billion
- AstraZeneca Sued Over Alleged Nexium Injuries, According to The Gibson Law Firm
April 20, 2011
- Galapagos Delivers Validated Oncology Targets to Janssen
- Abbott Reports 17.4 Percent Sales Growth and 12.3 Percent Ongoing Earnings-Per-Share Growth in First Quarter
- White House to Fight Prescription Drug Abuse
- Cumberland Pharmaceuticals Acquires Rights to Ifetroban Molecule
- Big Drug Firms Lost Big Money in Market Value
- Furiex Gets Sole Rights to Antibiotic
- Ligand Partner Prism Pharmaceuticals to be Acquired by Baxter
- Pfizer and Shanghai Pharmaceutical Sign Memorandum of Understanding for Potential Strategic Partnership
- FDA 'Strategic Priorities 2011 - 2015' Now Available
April 21, 2011
- Baxter's First Quarter Financial Results Exceed Guidance
- Amgen's First Quarter 2011 Revenue Increased 3 Percent to $3.7 Billion
- Biogen Idec Reports First Quarter 2011 Results
- N.C. Medical Lawsuit Limits Adjusted
- Amgen's 1st-Quarter Profit Falls on Higher Costs, but Bests Wall Street's Forecast
- Pfizer Makes China Plans With Shanghai Pharma
- University of Wisconsin Group Ends Drug Firm Funds
- Fourth Update on Daiichi Sankyo Operations Following the Great East Japan Earthquake
- Amgen Outlines Strategy, Growth Objectives and Capital Allocation Plans
April 22, 2011
- Feds' Move to Oust Drug Company Chief
- Pfizer Comments on ORAL Sync Tofacitinib Data in EULAR Abstract LB0005
- Important Drug Product Notice: Luitpold Pharmaceuticals, Inc. Announces Temporary Suspension of Distribution and Manufacture of Drug Products
- Idera Pharmaceuticals Delays Initiation of Phase 2 Clinical Trial of IMO-2125 in Treatment-Naïve HCV Patients
- Labcorp to Lay Off 169 Former Genzyme Workers
- Gilead Sciences Announces First Quarter 2011 Financial Results
- Pfizer Says Patient Died in Oral RA Drug Study
- Valeant Pharmaceuticals Responds to Cephalon Board's Letter
- Cephalon and Takeover Rival Play Their Cards
April 25, 2011
- Merck to Expand Facilities, Add Jobs
- AstraZeneca and POZEN File Patent Infringement Lawsuit Against Dr. Reddy's
- Wockhardt Receives US FDA Approval for Generic Version of Aricept Tablets
- Mylan Launches First Generic Version of Femara Tablets
- Doctors, Patients Recall Visit Differently
- PatientsLikeMe Social Network Refutes Published Clinical Trial
- FDA Says Highly Anticipated Merck Drug Eliminated Traces of Hepatitis C
- Taro Resolves FDA Warning Letter
- Pain Therapeutics Reports Remoxy Abuse Study Data
April 26, 2011
- Biogen Will Build Bigger Space
- Top Targacept Executives Get Raises
- Doctors' Rights to Pharmacy Data Argued
- Column: AstraZeneca to Raze Lab Space in Wilmington
- Diamyd Medical: Diamyd Replaces CEO
- Supreme Court To Hear Doctor Pharmacy Data Case
April 27, 2011
- Merck Announces New $5 Billion Share Repurchase Program
- Drug Scarcity Frustrates ADHD Patients
- New Generic Cancer Drugs Help Hospira to 6% Profit Increase
- Johnson & Johnson to Buy US-Swiss Medical Device Maker Synthes for $21.3 Billion
- Regeneron Pharmaceuticals, Sanofi-Aventis' Zaltrap Meets Goals
- FDA Approves Taro's Canadian Pharmaceutical Facility
- Watson First Quarter 2011 Net Revenue Increases to $877 Million
- Dainippon Sumitomo Pharma and Maruho Enter into a License Agreement for a Novel Topical Analgesic Drug
- Drug Shortages Hit Calif.
- GSK Q1 Performance Demonstrates Continued Progress With Delivery of Underlying Sales Growth, Cash Generation and Pipeline Visibility
- Final Appeal Briefing Issued in $16 Million Illinois Fentanyl Patch Lawsuit According to Heygood, Orr & Pearson
April 28, 2011
- Novo Nordisk's First-Quarter Profit Grows 23 Percent to $802 Million
- AstraZeneca Q1 Profit Rises Despite Revenue Drop
- Sanofi-Aventis Earnings Drop 29 Percent in First Quarter on Loss of Swine Flu Vaccine Sales
- Eli Lilly Says Court Blocks Generic Cymbalta
- Bristol-Myers Squibb Delivers Excellent First Quarter with YERVOY (ipilimumab) Approval, Key R&D Milestones and Strong Financials
- Merck and Inspire Announce Expiration of Hart-Scott-Rodino Act Waiting Period Relating to Tender Offer for Shares of Inspire
- Q1/2011: Merck Profit After Tax Jumps 77% to EUR 344 Million
- sanofi-aventis: Strong Performance of Growth Platforms in Q1 2011
- Shire Delivers a Strong First Quarter Performance
- Genzyme Revenues Grow in First-Quarter 2011
- Novo Nordisk Increased Operating Profit by 24% in the First Quarter of 2011 (28 April 2011)
- AstraZeneca Q1 Profit Rises Despite Revenue Drop
- Novo Nordisk's First-Quarter Profit Grows 23 Percent to $802 Million
- Bayer Raises Q1 Profit, Outlook on Strong Performance By Materials, Farm Divisions
- Sanofi-Aventis Earnings Drop 29 Percent in First Quarter on Loss of Swine Flu Vaccine Sales
- Merck's Big Day: A Share Buyback and FDA Panel Approval
- WebMD's First Annual Physician Compensation Survey Reveals Significant Income Disparities
- Iroko Pharmaceuticals Acquires iCeutica to Bolster Capabilities in Novel Low-Dose NSAIDs
- Bristol-Myers Squibb Delivers Excellent First Quarter with YERVOY (ipilimumab) Approval, Key R&D Milestones and Strong Financials
- Takeda Announces Establishment of a New Sales and Marketing Company in China
- Omnicare Clinical Research Acquired by Nautic Partners, LLC
April 29, 2011
- EU Probes Whether Deal to Keep Generic Provigil Off European Market Broke Competition Rules
- Merck Announces First Quarter 2011 Financial Results
- Human Genome Sciences Books Bigger 1Q loss
- Labopharm Provides Update on Strategic Review Process
- NeurogesX CEO Anthony DiTonno to Retire by Year End
- FDA Advisory Committee Unanimously Recommends Approval of Telaprevir for People with Hepatitis C
- Med Ad News Honors Healthcare Advertisers at 22nd Annual Manny Awards
- J&J CEO: Most Product Recalls Are Behind Us; With Changes, We'll Come Back Even Stronger
- EDITORIAL: Strong Medicine [Boston Herald]
- FDA Panel Unanimously Approves Experimental Hepatitis Drug From Vertex Pharma
- Avastin Proves As Good As Pricier Lucentis for Eye Disease Wet Macular Degeneration
- Pfizer Shareholders Get Annual Say on Pay
- Johnson & Johnson?s Concerta Scores Top Spot on First Digital IQ Index for Pharma Brands & Healthcare Providers
